An interventional study of 3D-printed custom applicator in Gynecologic Cancer, Endometrial Cancer and Vaginal Cancer, sponsored by Royal North Shore Hospital. Recruiting at 1 site in Australia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-06.
Sponsored by Royal North Shore Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Endometrial Neoplasms with a site in Australia — 38 open to participants now, 59 under way, 14 of them phase 3. Endometrial Neoplasms · Australia.
Among the 86 studies in Endometrial Neoplasms with a site in Australia, this one is the 79th largest by planned enrollment of the 80 interventional ones that give a count, is one of 12 that started in 2023, is one of 3 with no phase, reaches primary completion later than 43 of the 58 other live ones, and was the 58th registered.
1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.
Browse Endometrial Neoplasms studies →38 of the 86 studies in Endometrial Neoplasms with a site in Australia are open now. Recruiting first, the newest first:
Pfizer · Sites in Australia, United States, China and 2 more countries
Ages 18+ · Women only
Second Life Therapeutics · Sites in Australia
Ages 18+
Huahui Health · Sites in Australia, China
Ages 18–75
GlaxoSmithKline · Sites in Australia, United States, Argentina and 7 more countries
Ages 18+ · Women only
Eikon Therapeutics · Sites in Australia, United States, Austria and 12 more countries
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 33 · Phase 3 19
First in 1996; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 71 across 1,029 interventional studies indexed under Endometrial Neoplasms.
Median enrollment 257 across the 80 interventional studies, 88 across the 4 observational. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
68 of 86 have an industry lead sponsor. The 10 most frequent:
Royal North Shore Hospital is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Royal North Shore Hospital has 1 study filed under Endometrial Neoplasms — fewer than ten, so there is no comparison to draw.
20 of the studies in Endometrial Neoplasms with a site in Australia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05173987Phase 3Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) | 2027-05-27 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06533059Alterome Therapeutics, Inc.A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | 2026-12-29 |
| NCT06533332EtiraRx Australia Pty LtdA Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors | 2026-12-30 |
Add all 20 to your calendar (.ics) → With an account.
Among the 86 studies in Endometrial Neoplasms with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose distributions. This study is a Phase IIa non-randomised interventional pilot trial that will investigate the feasibility of successfully treating patients with 3D-printed custom applicators.
Intracavitary brachytherapy for gynaecological cancer currently use cylinder-type applicators or custom wax moulds to place a radioactive source in close proximity to the treatment area and provide highly conformal dose distributions. Current workflows for designing and constructing custom applicators with wax moulds are complex, time consuming and can result in a device that fails to meet original design specifications dictated by the planning system. In contrast, 3D-printed custom applicators provide the ability to design and print patient-specific devices that match optimal design specifications. The workflow for 3D-printed applicators is also more efficient with lower turn-around time and labour/equipment costs, and ensures a more robust product for treatment. Despite these advantages there is currently no radiotherapy department offering 3D printed custom applicators at present. This study will investigate the feasibility of successfully treating gynaecological cancers with 3D-printed custom applicators.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Using 3D-printed custom applicators to treat gynaecological HDR brachytherapy patients
Device: 3D-printed custom applicator
3D-printed custom applicator
Successful treatment of gynaecological HDR brachytherapy patients with 3D printed intracavitary applicators.
To demonstrate the feasibility of successfully simulating, planning and treating a HDR BT gynaecological patient with a 3D-printed internal mould, such that there is a dosimetric and/or clinical benefit for the patient relative to the current standard of care (cylindrical vaginal applicator). Successful treatment indicated by achieving no adverse events or difference to standard of care, and dosimentic comparisons of the 3D printed applicator plan to the cylinder plan are equivalent or better. Feasibility also determined by achieving no logistical or design issues in using the 3D printed applicators clinically.
Time frame: 5 years
To assess the patients radiation therapy acute and late toxicities using the CTCAE criteria
RT acute and late side effects will be assessed and quantified using CTCAE criteria via clinician assessment and PROs
Time frame: 5 years
To compare quality of treatment plans generated for 3D-printed moulds and cylindrical applicators assessed by dosimetric indices, statistical analysis (p-value) and comparison with international guidelines.
The plan quality of treatment plans generated for 3D-printed moulds and cylindrical applicators will be compared using dosimetric indices including target coverage (D90, Dose Homogeneity index) and organs at risk doses (D2cc, D1cc and point max) as well as patient comfort. statistical analysis (p-value) and comparison with international guidelines will be used to assess the quality of the treatment plans.
Time frame: 5 years
Determine feasibility of a pre-planned MR-only procedure
Feasibility of a pre-planned MR-only procedure will be determined using any of the patients that are accrued to the study who have both a CT and MRI performed at the time of simulation. The applicator and treatment plan will be generated based on the MRI and both compared to the CT-based plan and applicator. Feasibility will be indicated by generating equivalent plan quality and applicators from both methods.
Time frame: 5 years
To determine the feasibility of an initial CT-only process by comparing initial and final CT plan dosimetry assessed by dosimetric indices, clinical tolerances, and statistical analysis (p-value).
The initial and final CT plan dosimetry will be compared to determine the feasibility of an initial CT-only process. Clinically insignificant differences between the plan dosimetry metrics and all within clinical tolerances will be used to quantify the difference. statistical analysis (p-value) will be used to assess the quality of the treatment plans.
Time frame: 5 years
Determine feasibility of optimising 3D-printed applicator design based on the cylinder fitting procedure
The feasibility of an optimised 3D-printed applicator design based on the cylinder fitting procedure will be assessed by comparison of the 3D-printed clinical applicators with applicators derived from CT/MR of the vault in a relaxed state with an expansion applied based on the size of the cylinder applied in the fitting procedure. Feasibility will be determined by looking for a correlation between the size of the 3D printed clinical applicators and the size of the cylinders tolerated by the patient in the fitting procedure.
Time frame: 5 years
To measure resources such as procedure times and demonstrate acceptable timescales for the process
Procedure times will be recorded as per ARIA carepath tasks and time taken within the 3D-printed custom applicator workflow compared to the standard of care cylinder applicator workflow with equivalent or less time taken deemed acceptable
Time frame: 5 years
To define the resource costs associated with the 3D-printed design process and perform a cost comparison with the standard of care process
Costs associated with the 3D-printed design process will be defined and compared with the standard of care process via economic analysis of the resourcing and unit-price estimates in each arm of the respective workflows
Time frame: 5 years
To assess patient experience and acceptability of the process with questionnaires
Patient experience and acceptability of the 3D-printed simulation and treatment processes will be assessed with the EORTC QLQ-C30 questionnaires and success measured by comparison with the standard of care vaginal cylinder process. Questionnaires include questions with a scale of 1-4 where a higher number indicates a worse experience and a scale of 1-7 where a lower number indicates a worse experience.
Time frame: 5 years
Started Nov 2023 (actual). Primary completion is estimated for Sep 2028, 58 months after the start.
Of 194 non-industry interventional studies with no phase under Endometrial Neoplasms, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 76. This study's planned 58 months is above that.
Counting every sponsor, half of 200 studies reached it within 43 months; a quarter within 19 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Royal North Shore Hospital